Clinical Trial Update: Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) [Phase 3]

View source ↗

Summary

Phase 3 trial update (LAGOON) evaluating lurbinectedin as a single agent or with irinotecan compared with topotecan or irinotecan in relapsed small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Hycamtin (Topotecan)
• Zepzelca (lurbinectedin)

Snippet

Sponsor: PharmaMar | Conditions: Relapsed Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING